best casino sites 0

Share

Biogen CEO Michel Vounatsos to Step Aside After Alzheimer’s Drug Struggles

Company says it will eliminate the sales infrastructure for Aduhelm, saving $500 million annually

Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it yet. Illustration: Jacob Reynolds

Biogen Inc. is shedding Chief Executive Michel Vounatsos and effectively abandoning its high-profile Alzheimer’s disease treatment Aduhelm as it attempts to chart a best casino sites 0 course after Medicare’s devastating refusal to pay for it.

Biogen said Tuesday that Mr. Vounatsos, 60 years old, would continue to lead the company and remain on its board until a search for a best casino sites 0 CEO is completed. It also took steps that will effectively end its marketing of the Alzheimer’s drug.

To Read the Full Story

Continue reading your article with
a WSJ membership